stoxline Quote Chart Rank Option Currency Glossary
  
Sol-Gel Technologies Ltd. (SLGL)
8.13  -0.277 (-3.29%)    07-18 16:00
Open: 8.08
High: 8.3972
Volume: 3,060
  
Pre. Close: 8.4066
Low: 7.9823
Market Cap: 23(M)
Technical analysis
2025-07-18 4:44:35 PM
Short term     
Mid term     
Targets 6-month :  10.24 1-year :  11.96
Resists First :  8.76 Second :  10.24
Pivot price 7.73
Supports First :  7.58 Second :  6.84
MAs MA(5) :  8.21 MA(20) :  7.64
MA(100) :  6.65 MA(250) :  6.6
MACD MACD :  0.2 Signal :  0.1
%K %D K(14,3) :  73.8 D(3) :  71
RSI RSI(14): 59.3
52-week High :  16.5 Low :  0.6
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SLGL ] has closed below upper band by 27.9%. Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.41 - 8.45 8.45 - 8.49
Low: 7.88 - 7.93 7.93 - 7.97
Close: 8.05 - 8.13 8.13 - 8.2
Company Description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Headline News

Wed, 07 May 2025
Will Sol-Gel Deliver The First Preventive Treatment For Gorlin Syndrome? - RTTNews

Mon, 05 May 2025
Sol-Gel Technologies Announces Reverse Share Split to Regain Nasdaq Compliance - TipRanks

Thu, 01 May 2025
Sol-Gel Sets 10:1 Reverse Split: Key Details About Share Consolidation and Nasdaq Compliance Plan - Stock Titan

Tue, 18 Feb 2025
Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals - TipRanks

Wed, 20 Nov 2024
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know - Nasdaq

Tue, 26 Mar 2024
SLGL Stock Quote Price and Forecast - CNN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 1 (M)
Held by Insiders 70 (%)
Held by Institutions 24.2 (%)
Shares Short 26 (K)
Shares Short P.Month 15 (K)
Stock Financials
EPS -4.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.23
Profit Margin -107.8 %
Operating Margin -879.7 %
Return on Assets (ttm) -26.9 %
Return on Equity (ttm) -49.4 %
Qtrly Rev. Growth 121.1 %
Gross Profit (p.s.) -3.3
Sales Per Share 4.33
EBITDA (p.s.) -5.08
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -1.73
PEG Ratio 0
Price to Book value 1.12
Price to Sales 1.87
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android